Tech Company Financing Transactions

Endeavor BioMedicines Funding Round

Matrix Capital Management, Abrdn and Ally Bridge Group invested in a $132.5 million Series C funding round for Endeavor BioMedicines. The round was announced on 4/24/2024.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

514 Via de la Valle 203
Solana Beach, CA 92075
USA

Phone

(858) 537-1700

Website

www.endeavorbiomedicines.com

Email Address

[email protected]

Overview

Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis. The company is developing taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway, that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

John Hood

        

Chief Financial Officer

Raghu Saripalli

        

Chief Scientific Officer

Miguel De Los Rios

        

Browse more venture capital transactions:

Prev: 4/24/2024: Dripos venture capital transaction
Next: 4/24/2024: Parloa venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to record tech company VC transactions. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary